ZELTIQ Announces First Quarter 2015 Financial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ZELTIQ Announces First Quarter 2015 Financial Results

PLEASANTON, CA--(Marketwired - May 5, 2015) -

  • First quarter 2015 Adjusted EBITDA margin of 5.8% versus 15.0% loss in Q1 2014
  • First quarter GAAP net loss of $2.1 million, or ($0.06) per share, compared to GAAP net loss of $7.3 million, or ($0.20) per share in Q1 2014
  • Shipped 347 systems in Q1 2015 compared to 179 systems in Q1 2014, bringing total system installed base to 3,523 systems
  • 207,287 revenue cycles shipped in Q1 2015, up 64% compared to Q1 2014

ZELTIQ ® , ( NASDAQ : ZLTQ ) a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced financial results for the first quarter 2015.

Mark Foley, President and Chief Executive Officer, said, "We began the year with another strong quarter of execution on our strategic initiatives and maintaining our position as the market leader in the growing non-invasive fat reduction market. We delivered exceptional revenue growth in the first quarter with a 66% year-over-year increase, driven by very strong system placements, a record quarter for revenue cycles shipped and the strongest contribution from our international business to date. Further penetration into key international markets is a significant driver for our global expansion strategy and I am pleased with our early success. With the impressive results we continue to deliver both domestically and across our international markets, we are raising our full year 2015 revenue guidance to the range of $235 million to $238 million which includes an approximate $2 million negative impact related to currency headwinds."

Mr. Foley continued, "During the first quarter, we began to leverage the innovation of our controlled cooling technology through our R&D efforts, further establishing our leadership position in the market. In January, we launched our next generation CoolSmooth PRO™ applicator which incorporates use of our recent FDA clearance for treatments at colder temperatures. This enhanced version of our original CoolSmooth™ applicator will have reduced treatment and set-up times that should create a better overall patient experience. Early demand since its launch has been tremendous with nearly 1,000 already pre-sold prior to commencement of shipping last week. We expect to expand the innovative R&D work done on colder temperatures across other applicators as we move into 2016. The much anticipated launch of our CoolMini™ applicator for smaller fat pockets and the submental area, or chin fat, remains on track for a fourth quarter 2015 clearance with enrollment fully complete and final follow-ups finishing up in the next two weeks." 

Mr. Foley concluded, "Finally, we held the grand opening of our CoolSculpting University East Coast Training Center which was overwhelmingly successful and generated outstanding physician customer feedback. We received the following feedback from Susan Hughes, M.D., of Cherry Hill, New Jersey, ' This course blew me away. As a cosmetic surgical M.D., I was very skeptical about really needing to attend this course and giving up 2 days of my practice during the week. I got tired of my staff who previously attended knowing more than I did. After attending this great training course, I now understand Treatment to Transformation very well. The marketing and commitment of ZELTIQ to help promote this technology is commendable and appreciated. I'm upset that I didn't come sooner! '. We are very pleased with the positive impact CoolSculpting University is having on our customers and our CoolSculpting business and expect this dual-coast approach to further drive improved outcomes and increase practice revenues."

First Quarter 2015 Financial Review Total revenue for the first quarter 2015 was $51.6 million, consisting of $26.2 million of system revenue and $25.4 million of consumable revenue. This compares to total revenue of $31.0 million, consisting of $14.5 million of system revenue and $16.5 million of consumable revenue for the first quarter 2014. Total revenue cycles shipped increased 64% to 207,287 for the first quarter 2015, compared to 126,059 for the first quarter 2014.

Gross profit was $37.2 million, or 72% of revenue, for the first quarter 2015, compared to gross profit of $22.0 million, or 71% of revenue, for the first quarter 2014. Operating expenses for the first quarter 2015 were $38.9 million, compared to $29.2 million for the first quarter 2014.

Loss from operations for the first quarter 2015 was $1.7 million, compared to a loss from operations of $7.2 million for the first quarter 2014. Net loss for the first quarter 2015 was $2.1 million, or $0.06 per share, compared to a net loss of $7.3 million for the first quarter 2014, or $0.20 per share. Weighted average basic shares outstanding was 38.4 million for the first quarter 2015, compared to weighted average basic shares outstanding of 37.2 million for the first quarter 2014. 

On a non-GAAP basis, ZELTIQ reported Adjusted EBITDA of positive $3.0 million, or 5.8% of revenue, for the first quarter 2015, compared to negative $4.7 million, or -15.0% of revenue, for the first quarter 2014.

Cash and cash equivalents, short-term investments, and long-term investments were $44.3 million as of March 31, 2015 compared to $41.2 million as of March 31, 2014, and $49.7 million as of December 31, 2014.

Revised Full Year 2015 Financial Guidance ZELTIQ is updating its previously stated financial guidance for the full year 2015, provided on its fourth quarter 2014 earnings conference call

  • Revenue guidance in the range of $235 million to $238 million which includes approximately $2 million of currency headwinds; up from prior guidance of $230 million to $235 million
  • Consumable revenue of approximately 50% of total revenue; unchanged from prior guidance
  • Gross profit margin of approximately 71% of total revenue; unchanged from prior guidance
  • Operating expenses of approximately 70% of total revenue; down from prior guidance of 70% to 71%
  • Stock-based compensation, depreciation, and amortization expense of approximately 7% of total revenue; unchanged from prior guidance
  • Adjusted EBITDA margin of approximately 8% of total revenue; up from prior guidance of 7% to 8%

Additional information regarding ZELTIQ's results and guidance can be found in ZELTIQ's Supplemental Financial and Operational Information schedule by  CLICKING HERE or by visiting the Investor Relations section of ZELTIQ's website at www.zeltiq.com .

Use of Non-GAAP Financial Measures ZELTIQ has supplemented its GAAP net income (loss) with a non-GAAP measure of Adjusted EBITDA. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of ZELTIQ, and provides an additional meaningful comparison of results for current periods with previous operating results, and assists management in analyzing future trends, making strategic and business decisions and establishing internal budgets and forecasts. A reconciliation of non-GAAP Adjusted EBITDA to GAAP net income (loss) in the most directly comparable GAAP measure is provided in the schedule below.

There are limitations in using this non-GAAP financial measure because it is not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. This non-GAAP financial measure should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the ZELTIQ's consolidated financial statements prepared in accordance with GAAP and the reconciliations of the non-GAAP financial measure provided in the schedule below.

Conference Call ZELTIQ will hold a conference call today at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. The dial-in numbers are (877) 280-7291 for domestic callers and (707) 287-9361 for international callers. A live webcast of the conference call will be available online from the investor relations page of ZELTIQ's corporate website at www.coolsculpting.com .

A replay of the webcast will remain available on ZELTIQ's website, www.coolsculpting.com , until ZELTIQ releases its first quarter 2015 financial results. In addition, a telephonic replay of the call will be available until May 12, 2015. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the replay conference ID number 23684951.

About ZELTIQ ® Aesthetics ZELTIQ is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ's first commercial product, the CoolSculpting ®  System, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. It utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer.

Forward-Looking Statements The statements made in this press release regarding ZELTIQ's belief that FDA clearance to perform CoolSculpting procedures at colder temperatures will enhance efficacy, significantly reduce treatment and set- up times and should create a better overall patient experience, its expectations to leverage the innovative R&D work done on colder temperatures across other applicators as it moves into 2016, the timing of the launch of the CoolMini™ applicator, its expectations that its dual-coast approach will further drive improved outcomes and increase practice revenues, and its financial projections for 2015 and the statements under the caption "Full Year 2015 Financial Guidance," are forward-looking statements. The words "continue," "will", "expect", "should", "on track", "guidance" and similar words that denote future events or results identify these forward-looking statements. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond ZELTIQ's control and that could materially affect ZELTIQ's actual business operations and financial performance and condition. Factors that could cause actual results to differ from those contemplated by these forward-looking statements include, but are not limited to: less than anticipated growth in the number of physicians electing to purchase CoolSculpting Systems; patient demand for CoolSculpting procedures may be lower than ZELTIQ expects; product or procedure announcements by competitors may decrease demand for CoolSculpting procedures; ZELTIQ may incorrectly estimate or control its future expenditures; ZELTIQ's sales and marketing plans may fail to increase sales as ZELTIQ expects; technical difficulties may arise in the completion of development of CoolMini™; patients or physicians may not view the benefits of CoolSculpting procedures at colder temperatures to be the same as ZELTIQ does; as well as those other risks and uncertainties set forth in ZELTIQ's Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 10, 2014. These forward-looking statements speak only as of the date of this press release. ZELTIQ expressly disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events or otherwise.

         
ZELTIQ Aesthetics, Inc.
Condensed Consolidated Balance Sheets
(In thousands)
(Unaudited)
         
    March 31, 2015   December 31, 2014
ASSETS            
CURRENT ASSETS:            
  Cash and cash equivalents   $ 25,057   $ 28,649
  Short-term investments     15,822     16,286
  Accounts receivable, net     24,525     21,472
  Inventory     17,353     15,536
  Prepaid expenses and other current assets     7,384     7,060
    Total current assets     90,141     89,003
  Long-term investments     3,411     4,805
  Restricted cash     546     560
  Property and equipment, net     3,608     3,724
  Intangible asset, net     5,605     5,780
  Other assets     68     33
    Total assets   $ 103,379   $ 103,905
             
LIABILITIES AND STOCKHOLDERS' EQUITY            
CURRENT LIABILITIES:            
  Accounts payable   $ 7,297   $ 5,824
  Accrued liabilities     20,224     21,450
  Deferred revenue     5,674     5,069
  Current portion of capital lease obligations     121     120
      Total current liabilities     33,316     32,463
Long-term deferred revenue     472     622
Long-term capital lease obligations, less current portion     232     262
Other non-current liabilities     385     39
    Total liabilities   $ 34,405   $ 33,386
STOCKHOLDERS' EQUITY:            
    Total stockholders' equity     68,974     70,519
    Total liabilities and stockholders' equity   $ 103,379   $ 103,905
                 
                 
                 
ZELTIQ Aesthetics, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
(Unaudited)
             
    Three Months Ended  
    March 31,  
    2015     2014  
Revenue   $ 51,558     $ 30,975  
Cost of revenue     14,378       9,016  
  Gross profit     37,180       21,959  
Operating expenses:                
  Research and development     6,080       4,270  
  Sales and marketing     24,406       20,187  
  General and administrative     8,388       4,713  
    Total operating expenses     38,874       29,170  
Income (loss) from operations     (1,694 )     (7,211 )
Interest income (expense), net     13       19  
Other income (expense), net     (420 )     (66 )
Income (loss) before income taxes     (2,101 )     (7,258 )
Income tax expense     28       79  
Net income (loss)     (2,129 )     (7,337 )
Net income (loss) per share, basic   $ (0.06 )   $ (0.20 )
Weighted average shares of common stock outstanding used in computing net income (loss) per share, basic     38,383,022       37,215,697  
Net income (loss) per share, diluted   $ (0.06 )   $ (0.20 )
Weighted average shares of common stock outstanding used in computing net income (loss) per share, diluted     38,383,022       37,215,697  
                 
                 
                 
                 
ZELTIQ Aesthetics, Inc.  
Condensed Consolidated Statements of Cash Flows  
(In thousands)  
(Unaudited)  
        Three Months Ended  
        March 31,  
        2015     2014  
CASH FLOWS FROM OPERATING ACTIVITIES:          
  Net income (loss) $ (2,129 )   $ (7,337 )
  Adjustments to reconcile net income (loss) to net cash used in operating activities:              
    Depreciation and amortization   513       455  
    Stock-based compensation   4,150       2,105  
    Deferred income taxes   -       30  
    Amortization (accretion) of investment premium (discount), net   22       67  
    Provision for (recovery of) doubtful accounts receivable   123       -  
    Provision for excess and obsolete inventory   128       105  
    Loss on disposal and write-off of property and equipment   -       17  
    Changes in operating assets and liabilities:              
      Accounts receivable   (3,359 )     (2,088 )
      Inventory   (2,100 )     (6,291 )
      Prepaid expenses and other assets   (391 )     570  
      Deferred revenue, net of deferred costs   503       853  
      Accounts payable, accrued and other non-current liabilities   710       (829 )
      Net cash provided by (used in) operating activities   (1,830 )     (12,343 )
CASH FLOWS FROM INVESTING ACTIVITIES:              
  Purchase of investments   (4,070 )     (2,249 )
  Proceeds from sale of investments   -       1,000  
  Proceeds from maturity of investments   5,911       4,791  
  Purchase of property and equipment   (285 )     (559 )
  Change in restricted cash   -       (1 )
      Net cash provided by (used in) investing activities   1,556       2,982  
CASH FLOWS FROM FINANCING ACTIVITIES:              
  Principal payments on capital leases   (29 )     -  
  Proceeds from issuance of common stock upon exercise of stock options   1,346       640  
  Tax payments related to shares withheld for vested restricted stock units   (4,345 )     (2,546 )
  Tax effect of employee stock plans   16       -  
      Net cash provided by (used in) financing activities   (3,012 )     (1,906 )
Effect of exchange rate changes on cash and cash equivalents   (306 )     15  
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS   (3,592 )     (11,252 )
CASH AND CASH EQUIVALENTS-Beginning of period   28,649       25,798  
CASH AND CASH EQUIVALENTS-End of period $ 25,057     $ 14,546  
               
               
               
             
ZELTIQ Aesthetics, Inc.  
Reconciliation of Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation,  
Amortization and Stock-Based Compensation (Adjusted EBITDA)  
(In thousands, except for percentages)  
(Unaudited)  
             
    Three Months Ended  
    March 31,  
Dollars   2015     2014  
  Net income (loss), as reported   $ (2,129 )   $ (7,337 )
                 
Adjustments to net income (loss):                
  Interest income (expense) and other income (expense), net     407       47  
  Income tax expense     28       79  
  Depreciation and amortization     513       455  
  Stock-based compensation expense     4,150       2,105  
    Total adjustments to net income (loss)     5,098       2,686  
                 
Adjusted EBITDA   $ 2,969     $ (4,651 )
                 
                 
      Three Months Ended  
      March 31,  
As a Percentage of Revenue     2015       2014  
  Net income (loss), as reported     -4.1 %     -23.7 %
                 
  Adjustments to net income (loss):                
  Interest income (expense) and other income (expense), net     0.8 %     0.2 %
  Income tax expense     0.1 %     0.3 %
  Depreciation and amortization     1.0 %     1.4 %
  Stock-based compensation expense     8.0 %     6.8 %
    Total adjustments to net income (loss)     9.9 %     8.7 %
                 
Adjusted EBITDA Margin     5.8 %     -15.0 %
                 
                 
                 
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Illumina's Virtual Cell Win Raises Bigger AI Stakes

Updated Category News Views 76

A blind prediction contest is a useful place to separate glossy AI talk from actual biology. Illumina's BioInsight AI Lab took first place in Arc Institute's 2026 Virtual Cell Challenge, outperforming roughly 1,500 competitors on predictions of how cells would react when genes were knocked down. That is not a quarterly revenue number, and nobody should pretend otherwise....

Continue Reading
Botanica’s Illuminations Carries More Than Holiday Glow

Updated Category News Views 106

Two million lights are doing more than brightening up a few winter evenings in Wichita. Illuminations at Botanica returns from November 23, 2026, through January 2, 2027, and the pleasant part of this story is that the spectacle has a practical backbone: it is Botanica’s largest fundraiser. For a garden nonprofit, that matters a whole lot more than another shiny...

Continue Reading
Dario's Personify Panel Puts Distribution Model in Focus

Updated Category News Views 208

A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....

Continue Reading
Liquidity Services Faces a Brutal Revenue Reality Check

Updated Category News Views 33

A 19.17% opening haircut is the market ringing the fire alarm, not politely clearing its throat. Liquidity Services reported fiscal fourth-quarter revenue of $106.4 million, roughly 10% below the prior-year quarter, and shareholders got hit hard on November 19, 2026. That reaction is ugly, but it is not mysterious. When a company built around moving surplus inventory...

Continue Reading
Huawei's Financial AI Push Targets Scale, Not Demos

Updated Category News Views 79

Banking AI has reached the point where a clever chatbot barely moves the needle. Huawei's message at Singapore FinTech Festival 2026 was aimed squarely at that harder, more expensive problem: turning AI from a scattered pilot project into machinery a financial institution can operate, govern, repeat, and improve without handing over its crown jewels. Ownership Is the...

Continue Reading
DPR’s Parent Benefits Signal a Tougher Labor Market

Updated Category News Views 34

Concrete Schedules Do Not Bend Easily A jobsite does not care that daycare closes at 6 p.m., and that is exactly why DPR Construction’s latest workplace recognition deserves a closer look. The privately held, employee-owned contractor landed at No. 29 among large companies on the 2026 Fortune Best Workplaces for Parents list. It is not a quarterly earnings event, and...

Continue Reading
Movement Elevates a Longtime Insider as Its New CEO

Updated Category News Views 87

Chalk dust rarely makes headlines, yet this is the sort of leadership change that can decide whether a consumer brand keeps its footing. Movement Climbing, Yoga and Fitness named Ryan Sewell chief executive officer effective November 18, 2026, with Anne-Worley Moelter moving into the chairperson role. It is a conspicuously internal handoff: Sewell started at the Boulder...

Continue Reading
Global-E Faces Fresh Scrutiny After Muted Quarterly Outlook

Updated Category News Views 39

A guidance bump that barely clears the curb can still wreck a stock. That is the unpleasant read-through from Global-E Online's third-quarter 2026 report: revenue guidance went higher, but not high enough to persuade investors that the business was pulling away from expectations. Shares fell after the release, and a securities-law investigation announced November 19 has...

Continue Reading
Arizona's Dry Climate Puts Scalp Health Under Stress

Updated Category News Views 16

Desert weather is unforgiving, and apparently the scalp does not get a pass. In a Nov. 20, 2026 discussion, Scottsdale and Tucson hair-restoration physician Dr. Sharon A. Keene frames Arizona hair concerns around something easy to overlook: the condition of the skin beneath the hair. That is a more sensible starting point than treating every strand in the shower like it...

Continue Reading
Chipotle's Thanksgiving BOGO Tests Loyalty Muscle Again

Updated Category News Views 35

Thanksgiving Eve is a peculiar little battlefield for restaurant chains: everybody wants the reunion crowd, nobody wants to give away the register. Chipotle is stepping back into it on Wednesday, November 25, with its Back Home BOGO for Rewards members from 5 to 9 p.m. local time at participating U.S. restaurants. Buy an entrée in person, scan the Rewards account, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Westpac's CEO Calls for Enhanced Social Media Fraud Measures

Updated Category News Views 140

Westpac's Urgent Plea for Enhanced Fraud Prevention Westpac Banking Corp's CEO has made a significant call for social media companies, including Meta Platforms, to take a more proactive role in fighting online financial fraud. With an alarming rise in scams targeting consumers, this appeal highlights the urgent need for a united front against fraudulent activities online....

Continue Reading
Empowering Veterans: Bombardier's Commitment to Career Success

Updated Category News Views 170

Empowering Veterans Through Partnership with the Army Today, Bombardier proudly announces its partnership with the U.S. Army via the Partnership for Your Success (PaYS) Program. This initiative is designed to connect service members with valuable civilian career opportunities, ensuring they receive guaranteed job interviews with participating employers. This strategic...

Continue Reading
AWH Faces Market Challenges with Stock at Record Low

Updated Category News Views 107

AWH Stock Experiences Significant Decline AWH stock has recently dropped to a concerning 52-week low of $0.38, reflecting the tough market conditions. The dip in stock price highlights the company’s struggles, with its market capitalization now at a mere $6.5 million. Over the past year, the stock has lost approximately 90.68% of its value, showcasing a substantial...

Continue Reading
Vimeo's Q3 2024 Financial Insights and Future Outlook

Updated Category News Views 370

Vimeo Posts Third Quarter 2024 Financial Update Vimeo recently shared its financial snapshot for the third quarter of 2024, showcasing the company's growth trajectory and key achievements. The shareholder letter is now available on the investor relations section of their website, allowing stakeholders to delve into the details. This transparency is vital for maintaining...

Continue Reading
Implantica's Year-End Report Highlights RefluxStop Progress

Updated Category News Views 165

Implantica's Year-End Report: Driving Forward with Innovation Implantica has made significant strides in the healthcare sector, particularly with its innovative product, RefluxStop™, which aims to transform how gastroesophageal reflux is treated. This year-end report presents a comprehensive overview of the company's achievements for the year. RefluxStop™ FDA...

Continue Reading